Drug Combination Details
| General Information of the Combination (ID: C76543) | |||||
|---|---|---|---|---|---|
| Name | Flavopiridol NP Info | + | Carfilzomib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Adrenocortical carcinoma
[ICD-11: 2D11]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | NCI-H295R | CVCL_0458 | Adrenal cortex carcinoma | Homo sapiens | ||
| SW13 | CVCL_0542 | Adrenal cortex carcinoma | Homo sapiens | |||
| In-vivo Model | A total of 5*106 NCI-H295R cells with luciferase reporter were injected into each flank of a Nu/Nu mouse (two xenografts per mouse). | |||||
| Experimental
Result(s) |
Treatment with flavopiridol and carfilzomib in all three ACC cell lines resulted in a dose-dependent, anti-proliferative effect, and the combination had synergistic activity as well as in three-dimensional tumor spheroids. The combination treatment increased G2M cell-cycle arrest and apoptosis, and decreased XIAP protein expression in ACC cell lines. | |||||
